Albany Molecular Research (AMRI) Given Daily Coverage Optimism Rating of 0.12

Press coverage about Albany Molecular Research (NASDAQ:AMRI) has trended somewhat positive on Friday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Albany Molecular Research earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3835520565441 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

• Goelzer Investment Management Cut Celgene (CELG) Stake; PGT (PGTI) Has 1.02 Sentiment (vothemes.com)
• Albany Molecular Research : AMRI) Shares Bought by Bank of America Corp DE (4-traders.com)
• 41.3% Return Seen to Date on SmarTrend Albany Molecular Call (AMRI) (mysmartrend.com)
• Albany Molecular Research, Inc. (NASDAQ:AMRI) Files An 8-K Submission of Matters to a Vote of Security Holders (4-traders.com)
• AMRI shareholders approve sale of company (finance.yahoo.com)

Several equities analysts recently issued reports on AMRI shares. First Analysis lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th. William Blair reiterated an “outperform” rating on shares of Albany Molecular Research in a research report on Tuesday, May 23rd. BidaskClub upgraded Albany Molecular Research from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Morgan Stanley lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective for the company. in a research report on Thursday, May 11th. They noted that the move was a valuation call. Finally, J P Morgan Chase & Co lowered Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. Five analysts have rated the stock with a hold rating, The company presently has a consensus rating of “Hold” and an average target price of $18.00.

Albany Molecular Research (AMRI) opened at 21.72 on Friday. The firm’s market capitalization is $904.99 million. The company has a 50 day moving average price of $21.71 and a 200 day moving average price of $18.30. Albany Molecular Research has a 12 month low of $13.01 and a 12 month high of $22.17.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.